ArticleJournal of thoracic disease2026
Idiopathic pulmonary fibrosis and interleukins: a bibliometric analysis [1999-2025].
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a long-term lung condition, with limited therapeutic options and an overall poor prognosis. Accumulating evidence indicates that interleukins (ILs) are essential for the initiation and course of IPF, with certain IL signaling pathways contributing to disease pathogenesis while simultaneously emerging as potential therapeutic targets. This study aims to highlight the progress and current research priorities in the field of IPF and ILs, thereby laying the foundations for the development of targeted therapies for IPF. Methods: In this study, research articles and clinical studies related to IPF and ILs were retrieved from the Web of Science Core Collection (WOSCC) and PubMed databases. Bibliometric and visual analyses were performed using CiteSpace 6.3.R3, VOSviewer 1.6.20, the R package bibliometrix, and SCImago Graphica to systematically characterize the research landscape and identify emerging hotspots in this field. Results: A total of 832 publications and 15 clinical studies were included. The results demonstrate a steadily increasing research interest in the IPF-IL field, with analyses of references and keywords highlighting disease mechanism elucidation and therapeutic strategy development as the dominant research themes. Keyword burst analysis further indicates sustained prominence of topics such as pirfenidone, diagnosis, and fibrosis, suggesting their relevance to current and near-future research directions. Conclusions: Overall, this study constructs a structured knowledge map of the IPF-IL research landscape, identifies potential avenues for future investigation, and offers priority guidance for subsequent mechanistic validation, clinical stratification, and therapeutic efficacy prediction in IPF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.